Standard BioTools (LAB) Stock Forecast, Price Target & Predictions
LAB Stock Forecast
Standard BioTools stock forecast is as follows: an average price target of $3.25 (represents a 62.50% upside from LAB’s last price of $2.00) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
LAB Price Target
The average price target for Standard BioTools (LAB) is $3.25 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $3.25 to $3.25. This represents a potential 62.50% upside from LAB's last price of $2.00.
LAB Analyst Ratings
According to 3 Wall Street analysts, Standard BioTools's rating consensus is 'Buy'. The analyst rating breakdown for LAB stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Standard BioTools Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 04, 2024 | Matthew Stanton | Jefferies | $3.25 | $2.66 | 22.18% | 62.50% |
The latest Standard BioTools stock forecast, released on Apr 04, 2024 by Matthew Stanton from Jefferies, set a price target of $3.25, which represents a 22.18% increase from the stock price at the time of the forecast ($2.66), and a 62.50% increase from LAB last price ($2.00).
Standard BioTools Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $3.25 |
| Last Closing Price | $2.00 | $2.00 | $2.00 |
| Upside/Downside | -100.00% | -100.00% | 62.50% |
In the current month, the average price target of Standard BioTools stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Standard BioTools's last price of $2.00. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Apr 16, 2024 | Cowen & Co. | - | Buy | Initialise |
| Apr 04, 2024 | Jefferies | - | Buy | Initialise |
| Jul 12, 2023 | KeyBanc | - | Overweight | Initialise |
Standard BioTools's last stock rating was published by Cowen & Co. on Sep 16, 2024. The company gave LAB a "Buy" rating, the same as its previous rate.
Standard BioTools Financial Forecast
Standard BioTools Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $28.19M | $25.37M | $27.67M | $25.12M | $27.02M | $25.65M | $18.78M | $26.50M | $38.27M | $28.50M | $31.02M | $32.79M | $44.61M | $39.86M | $26.06M | $27.62M | $32.44M | $26.50M | $28.20M | $30.11M |
| Avg Forecast | $55.00M | $50.05M | $46.35M | $48.70M | $47.02M | $41.30M | $48.25M | $46.01M | $24.90M | $23.60M | $24.20M | $28.36M | $38.00M | $30.95M | $29.78M | $25.65M | $32.67M | $30.00M | $30.99M | $32.39M | $50.70M | $32.47M | $19.07M | $29.05M | $30.94M | $28.74M | $30.16M | $29.20M |
| High Forecast | $56.58M | $51.49M | $47.69M | $50.10M | $48.38M | $41.35M | $49.64M | $47.33M | $25.62M | $24.28M | $24.90M | $29.18M | $39.09M | $31.84M | $30.22M | $26.03M | $33.16M | $30.44M | $31.45M | $32.87M | $51.45M | $32.95M | $19.35M | $29.48M | $31.40M | $29.16M | $30.61M | $29.63M |
| Low Forecast | $51.94M | $47.26M | $43.77M | $45.99M | $44.40M | $41.25M | $45.56M | $43.44M | $23.51M | $22.29M | $22.85M | $26.78M | $35.88M | $29.23M | $28.94M | $24.93M | $31.76M | $29.16M | $30.12M | $31.48M | $49.28M | $31.56M | $18.54M | $28.23M | $30.07M | $27.93M | $29.32M | $28.38M |
| # Analysts | - | - | - | - | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | 1.13% | 1.07% | 1.14% | 0.89% | 0.71% | 0.83% | 0.63% | 1.03% | 1.17% | 0.95% | 1.00% | 1.01% | 0.88% | 1.23% | 1.37% | 0.95% | 1.05% | 0.92% | 0.93% | 1.03% |
Standard BioTools's average Quarter revenue forecast for Mar 24 based on 0 analysts is $46.01M, with a low forecast of $43.44M, and a high forecast of $47.33M. LAB's average Quarter revenue forecast represents a 63.21% increase compared to the company's last Quarter revenue of $28.19M (Dec 23).
Standard BioTools EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | $-21.39M | $-21.17M | $-17.45M | $-11.80M | $-15.97M | $-25.49M | $-37.97M | $-23.41M | $-5.29M | $-10.43M | $-12.87M | $-15.69M | $-12.14M | $-1.39M | $-9.37M | $-11.70M | $-4.75M | $-9.68M | $-10.45M | $-9.73M |
| Avg Forecast | $-25.68M | $-23.37M | $-21.64M | $-22.74M | $-21.95M | $-19.28M | $-22.53M | $-21.48M | $-11.63M | $-11.02M | $-11.30M | $-13.24M | $-17.74M | $-14.45M | $-13.90M | $-11.98M | $-15.26M | $-14.01M | $-14.47M | $-15.12M | $-23.67M | $-15.16M | $-8.90M | $-13.56M | $-14.45M | $-13.42M | $-14.08M | $-13.63M |
| High Forecast | $-24.25M | $-22.07M | $-20.44M | $-21.47M | $-20.73M | $-19.26M | $-21.27M | $-20.28M | $-10.98M | $-10.41M | $-10.67M | $-12.50M | $-16.75M | $-13.65M | $-13.51M | $-11.64M | $-14.83M | $-13.61M | $-14.06M | $-14.70M | $-23.01M | $-14.74M | $-8.65M | $-13.18M | $-14.04M | $-13.04M | $-13.69M | $-13.25M |
| Low Forecast | $-26.42M | $-24.04M | $-22.27M | $-23.39M | $-22.59M | $-19.31M | $-23.18M | $-22.10M | $-11.96M | $-11.34M | $-11.63M | $-13.62M | $-18.25M | $-14.87M | $-14.11M | $-12.15M | $-15.48M | $-14.22M | $-14.68M | $-15.35M | $-24.02M | $-15.39M | $-9.04M | $-13.76M | $-14.66M | $-13.62M | $-14.29M | $-13.83M |
| Surprise % | - | - | - | - | - | - | - | - | 1.84% | 1.92% | 1.54% | 0.89% | 0.90% | 1.76% | 2.73% | 1.95% | 0.35% | 0.74% | 0.89% | 1.04% | 0.51% | 0.09% | 1.05% | 0.86% | 0.33% | 0.72% | 0.74% | 0.71% |
undefined analysts predict LAB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Standard BioTools's previous annual EBITDA (undefined) of $NaN.
Standard BioTools Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | $-19.78M | $-21.00M | $-17.04M | $-16.84M | $-20.84M | $-29.43M | $-63.54M | $-76.29M | $-9.43M | $-13.84M | $-17.14M | $-18.82M | $-18.03M | $-6.00M | $-13.02M | $-15.98M | $-12.69M | $-12.89M | $-13.75M | $-25.46M |
| Avg Forecast | $-14.89M | $-16.75M | $-18.62M | $-26.06M | $-28.55M | $-32.27M | $-31.03M | $-41.84M | $-89.36M | $-85.64M | $-78.19M | $-20.60M | $-40.96M | $-48.40M | $-48.40M | $-55.85M | $-104.25M | $-81.91M | $-72.60M | $-69.74M | $-24.39M | $-74.52M | $-85.68M | $-71.09M | $-70.74M | $-74.87M | $-77.40M | $-93.56M |
| High Forecast | $-13.82M | $-15.54M | $-17.27M | $-24.18M | $-26.48M | $-29.93M | $-28.78M | $-38.81M | $-82.89M | $-79.44M | $-72.53M | $-19.11M | $-37.99M | $-44.90M | $-46.64M | $-53.81M | $-100.45M | $-78.92M | $-69.96M | $-67.20M | $-23.50M | $-71.80M | $-82.56M | $-68.50M | $-68.16M | $-72.14M | $-74.57M | $-90.15M |
| Low Forecast | $-15.45M | $-17.38M | $-19.31M | $-27.04M | $-29.61M | $-33.48M | $-32.19M | $-43.41M | $-92.71M | $-88.85M | $-81.12M | $-21.38M | $-42.49M | $-50.22M | $-49.33M | $-56.93M | $-106.26M | $-83.49M | $-74.00M | $-71.09M | $-24.86M | $-75.95M | $-87.33M | $-72.46M | $-72.11M | $-76.31M | $-78.89M | $-95.37M |
| Surprise % | - | - | - | - | - | - | - | - | 0.22% | 0.25% | 0.22% | 0.82% | 0.51% | 0.61% | 1.31% | 1.37% | 0.09% | 0.17% | 0.24% | 0.27% | 0.74% | 0.08% | 0.15% | 0.22% | 0.18% | 0.17% | 0.18% | 0.27% |
Standard BioTools's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LAB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Standard BioTools SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | $21.35M | $22.29M | $22.60M | $22.31M | $23.90M | $29.60M | $30.38M | $30.88M | $22.96M | $24.07M | $24.25M | $27.61M | $31.93M | $22.66M | $20.62M | $22.70M | $18.79M | $20.73M | $22.13M | $22.82M |
| Avg Forecast | $45.99M | $41.86M | $38.76M | $40.73M | $39.32M | $34.54M | $40.35M | $38.47M | $20.82M | $19.74M | $20.24M | $23.72M | $31.78M | $25.88M | $24.90M | $21.45M | $27.32M | $25.09M | $25.92M | $27.08M | $42.40M | $27.16M | $15.95M | $24.29M | $25.87M | $24.03M | $25.22M | $24.42M |
| High Forecast | $47.32M | $43.06M | $39.88M | $41.90M | $40.45M | $34.58M | $41.51M | $39.58M | $21.42M | $20.30M | $20.82M | $24.40M | $32.69M | $26.63M | $25.27M | $21.77M | $27.73M | $25.46M | $26.30M | $27.48M | $43.03M | $27.56M | $16.18M | $24.65M | $26.26M | $24.39M | $25.60M | $24.78M |
| Low Forecast | $43.43M | $39.52M | $36.60M | $38.46M | $37.13M | $34.50M | $38.10M | $36.33M | $19.66M | $18.64M | $19.11M | $22.40M | $30.01M | $24.44M | $24.21M | $20.85M | $26.56M | $24.38M | $25.19M | $26.32M | $41.21M | $26.39M | $15.50M | $23.61M | $25.15M | $23.36M | $24.52M | $23.73M |
| Surprise % | - | - | - | - | - | - | - | - | 1.03% | 1.13% | 1.12% | 0.94% | 0.75% | 1.14% | 1.22% | 1.44% | 0.84% | 0.96% | 0.94% | 1.02% | 0.75% | 0.83% | 1.29% | 0.93% | 0.73% | 0.86% | 0.88% | 0.93% |
Standard BioTools's average Quarter SG&A projection for Mar 24 is $38.47M, based on 0 Wall Street analysts, with a range of $36.33M to $39.58M. The forecast indicates a 80.17% rise compared to LAB last annual SG&A of $21.35M (Dec 23).
Standard BioTools EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | $-0.25 | $-0.27 | $-0.22 | $-0.21 | $-0.26 | $-0.37 | $-0.82 | $-0.99 | $-0.12 | $-0.18 | $-0.23 | $-0.25 | $-0.24 | $-0.08 | $-0.18 | $-0.23 | $-0.18 | $-0.19 | $-0.20 | $-0.44 |
| Avg Forecast | $-0.04 | $-0.04 | $-0.05 | $-0.07 | $-0.08 | $-0.09 | $-0.08 | $-0.11 | $-0.24 | $-0.23 | $-0.21 | $-0.06 | $-0.11 | $-0.13 | $-0.13 | $-0.15 | $-0.28 | $-0.22 | $-0.20 | $-0.19 | $-0.07 | $-0.20 | $-0.23 | $-0.19 | $-0.19 | $-0.20 | $-0.21 | $-0.25 |
| High Forecast | $-0.04 | $-0.04 | $-0.05 | $-0.06 | $-0.07 | $-0.08 | $-0.08 | $-0.10 | $-0.22 | $-0.21 | $-0.19 | $-0.05 | $-0.10 | $-0.12 | $-0.13 | $-0.14 | $-0.27 | $-0.21 | $-0.19 | $-0.18 | $-0.06 | $-0.19 | $-0.22 | $-0.18 | $-0.18 | $-0.19 | $-0.20 | $-0.24 |
| Low Forecast | $-0.04 | $-0.05 | $-0.05 | $-0.07 | $-0.08 | $-0.09 | $-0.09 | $-0.12 | $-0.25 | $-0.24 | $-0.22 | $-0.06 | $-0.11 | $-0.13 | $-0.13 | $-0.15 | $-0.29 | $-0.22 | $-0.20 | $-0.19 | $-0.07 | $-0.20 | $-0.23 | $-0.19 | $-0.19 | $-0.20 | $-0.21 | $-0.26 |
| Surprise % | - | - | - | - | - | - | - | - | 1.04% | 1.17% | 1.05% | 3.79% | 2.36% | 2.85% | 6.31% | 6.60% | 0.43% | 0.82% | 1.18% | 1.33% | 3.66% | 0.41% | 0.78% | 1.20% | 0.95% | 0.94% | 0.96% | 1.75% |
According to undefined Wall Street analysts, Standard BioTools's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LAB previous annual EPS of $NaN (undefined).
Standard BioTools Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LMDX | LumiraDx | $0.02 | $1.50 | 7400.00% | Buy |
| NDRA | ENDRA Life Sciences | $0.23 | $5.00 | 2073.91% | Buy |
| DRIO | DarioHealth | $0.87 | $10.75 | 1135.63% | Buy |
| STIM | Neuronetics | $0.95 | $8.00 | 742.11% | Buy |
| MDXH | MDxHealth SA | $2.61 | $15.00 | 474.71% | Buy |
| NOTV | Inotiv | $1.78 | $9.00 | 405.62% | Hold |
| GTH | Genetron | $4.03 | $10.00 | 148.14% | - |
| BDSX | Biodesix | $1.80 | $3.00 | 66.67% | Buy |
| LAB | Standard BioTools | $2.00 | $3.25 | 62.50% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |
LAB Forecast FAQ
Is Standard BioTools a good buy?
Yes, according to 3 Wall Street analysts, Standard BioTools (LAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of LAB's total ratings.
What is LAB's price target?
Standard BioTools (LAB) average price target is $3.25 with a range of $3.25 to $3.25, implying a 62.50% from its last price of $2. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Standard BioTools stock go up soon?
According to Wall Street analysts' prediction for LAB stock, the company can go up by 62.50% (from the last price of $2 to the average price target of $3.25), up by 62.50% based on the highest stock price target, and up by 62.50% based on the lowest stock price target.
Can Standard BioTools stock reach $3?
LAB's average twelve months analyst stock price target of $3.25 supports the claim that Standard BioTools can reach $3 in the near future.
What are Standard BioTools's analysts' financial forecasts?
Standard BioTools's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $182.57M (high $186.69M, low $174.66M), average EBITDA is $-85.248M (high $-81.551M, low $-87.171M), average net income is $-134M (high $-124M, low $-139M), average SG&A $152.68M (high $156.13M, low $146.06M), and average EPS is $-0.359 (high $-0.333, low $-0.372). LAB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $200.1M (high $205.87M, low $188.96M), average EBITDA is $-93.431M (high $-88.228M, low $-96.123M), average net income is $-76.328M (high $-70.802M, low $-79.187M), average SG&A $167.34M (high $172.16M, low $158.02M), and average EPS is $-0.205 (high $-0.19, low $-0.213).
Did the LAB's actual financial results beat the analysts' financial forecasts?
Based on Standard BioTools's last annual report (Dec 2023), the company's revenue was $106.34M, beating the average analysts forecast of $101.06M by 5.22%. Apple's EBITDA was $-76.6M, beating the average prediction of $-47.187M by 62.33%. The company's net income was $-74.656M, missing the average estimation of $-274M by -72.73%. Apple's SG&A was $87.54M, beating the average forecast of $84.51M by 3.58%. Lastly, the company's EPS was $-0.94, beating the average prediction of $-0.735 by 27.83%. In terms of the last quarterly report (Dec 2023), Standard BioTools's revenue was $28.19M, beating the average analysts' forecast of $24.9M by 13.20%. The company's EBITDA was $-21.386M, beating the average prediction of $-11.626M by 83.94%. Standard BioTools's net income was $-19.776M, missing the average estimation of $-89.359M by -77.87%. The company's SG&A was $21.35M, beating the average forecast of $20.82M by 2.55%. Lastly, the company's EPS was $-0.25, beating the average prediction of $-0.24 by 4.17%